Blood biomarkers of peripheral neuropathy

Acta Neurol Scand. 2022 Oct;146(4):325-331. doi: 10.1111/ane.13650. Epub 2022 May 25.

Abstract

Traditionally, neurophysiology is the primary diagnostic and prognostic biomarker in peripheral neuropathy clinical practice; however, it may lack responsiveness in the context of slowly progressive neuropathies and where there is significant axonal damage. The development of ultrasensitive platforms for measuring serum proteins at the lower limit of detection of traditional ELISA techniques has transformed the field of blood biomarkers of peripheral neuropathy. A variety of blood biomarkers have been identified from inflammatory cytokines and apokines in diabetic neuropathy through to neuron-specific proteins such as neurofilament light chain, Schwann cell-specific proteins such as TMPRSS5 and microRNAs in other acquired and hereditary neuropathies. In this article, we review blood biomarkers of disease activity for the common subtypes of peripheral neuropathy including inflammatory demyelinating neuropathies, vasculitic neuropathy, diabetic neuropathy, chemotherapy-induced neuropathy and Charcot-Marie-Tooth disease and related disorders including TTR amyloidosis.

Keywords: Biomarkers; Blood; Peripheral neuropathy.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents*
  • Biomarkers
  • Charcot-Marie-Tooth Disease* / metabolism
  • Cytokines
  • Humans
  • MicroRNAs*

Substances

  • Antineoplastic Agents
  • Biomarkers
  • Cytokines
  • MicroRNAs